Untitled Document

Meeting Overview

We are pleased to invite you to the Multidisciplinary Expert PracticeSM in Breast Cancer in Brussels, Belgium on 12-13 November 2010.

During this case-based meeting, leaders in the field discuss with participants, in an interactive format, clinical issues encountered daily by practicing physicians.

The Multidisciplinary Workshop on Friday will include 5 clinical scenarios for which attendees will be asked to provide their diagnostic and therapeutic opinions. A renowned, multidisciplinary faculty will review imaging, histology slides, and surgical techniques.




For available travel grants, please contact: travelgrants@prIMEoncology.org.

Target Audience

This educational activity is designed for Pan-European medical oncologists, radiation oncologists, surgical oncologists, pathologists and other healthcare providers involved active in the management of patients with breast cancer.

Meeting Venue

The Brussels Marriott Hotel
Rue Auguste Orts 3-7/ Grand Place
1000 Brussels, Belgium

Faculty

Co-Chairs:    
Christos Markopoulos, MD, PhD 
Athens University Medical School
Athens, Greece   
             Cornelis van de Velde, MD, PhD
Leiden University
Leiden, the Netherlands
     
Faculty:    
Ahmad Awada, MD, PhD   
Institute Jules Bordet
Brussels, Belgium
  Robert Coleman, MD
Weston Park Hospital
Sheffield, United Kingdom
Ian Kunkler, MD
University of Edinburgh
Edinburgh, Scotland
  Ariel Saracco, MD
Bröstcentrum SöS
Södersjukhuset
Stockholm, Sweden
Giuseppe Viale, MD, PhD
European Institute of Oncology
Milan, Italy
 

Agenda

Friday, 12 November 2010

17.00-
19.00

  Multidisciplinary Workshop
The how, when, and why of modern breast cancer management

Christos Markopoulos, MD, PhD; Cornelis van de Velde, MD, PhD; Ariel Saracco, MD; Giuseppe Viale, MD, PhD

19.30   Reception and buffet dinner
Saturday, 13 November 2010
07.30   Breakfast
08.30   Welcome and demographic questions
prIME Medical Director/Co-chairs
08.50   Hot topics in breast oncology in 2010
Rob Coleman, MD; Ian Kunkler, MD;
Christos Markopoulos, MD, PhD; Giuseppe Viale, MD, PhD
09.30   Case #1—Endocrine-responsive postmenopausal breast cancer - a clinicopathology discussion
All Faculty
10.15   Bone-targeted agents: What’s new and what’s next?
Robert Coleman, MD
10.30   Break
10.50   Case #2T3 breast cancer in a postmenopausal patient
Cornelis van de Velde, MD, PhD
11.20   Case #3HER2-positive breast cancer in a premenopausal patient with cardiac risk - a clinicopathology discussion
All Faculty
12.05   Clinical opinion poll questions
12.30   Lunch
13.30   Case #4Managing metastatic breast cancer in a patient previously treated with an anthracycline and taxane
Ahmad Awada, MD, PhD
14.00   Triple-negative breast cancer (TNBC): A demographic and molecular perspective
Giuseppe Viale, MD, PhD
14.20   Case #5Metastatic TNBC
Ahmad Awada, MD, PhD
14.50   Case #6Metastatic HER2-positive breast cancer with CNS metastases - a clinicopathology discussion
All Faculty
15.30   Program “pearls” and concluding remarks
Christos Markopoulos, MD, PhD
Cornelis van de Velde, MD, PhD
15.45   Adjourn

Program Slides

Print Materials







Accreditation

This meeting is accreditated by


'Multidisciplinary Expert Practice in Breast Cancer Management’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

‘Multidisciplinary Expert Practice in Breast Cancer Management’ is designated for a maximum of 8 hours of European external CME credits. Each Medical Specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA Category 1Credit ™ , contact the AMA.
UEMS

This meeting is endorsed by ESSO.
UEMS

Support

Support for this activity is provided by Eisai Europe Limited; Genomic Health, Inc.; GlaxoSmithKline; Novartis Oncology and sanofi-aventis.










Organizer

This meeting is a prIME Oncology activity.